- Home
- SNDX vs FCF Comparison
SNDX vs FCF Comparison
Compare SNDX & FCF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNDX
- FCF
- Stock Information
- Founded
- SNDX 2005
- FCF 1934
- Country
- SNDX United States
- FCF United States
- Employees
- SNDX N/A
- FCF N/A
- Industry
- SNDX Biotechnology: Pharmaceutical Preparations
- FCF Major Banks
- Sector
- SNDX Health Care
- FCF Finance
- Exchange
- SNDX Nasdaq
- FCF Nasdaq
- Market Cap
- SNDX 1.1B
- FCF 1.6B
- IPO Year
- SNDX 2016
- FCF N/A
- Fundamental
- Price
- SNDX $9.00
- FCF $17.26
- Analyst Decision
- SNDX Strong Buy
- FCF Buy
- Analyst Count
- SNDX 10
- FCF 8
- Target Price
- SNDX $35.80
- FCF $19.00
- AVG Volume (30 Days)
- SNDX 1.8M
- FCF 560.5K
- Earning Date
- SNDX 07-31-2025
- FCF 07-22-2025
- Dividend Yield
- SNDX N/A
- FCF 3.13%
- EPS Growth
- SNDX N/A
- FCF N/A
- EPS
- SNDX N/A
- FCF 1.34
- Revenue
- SNDX $43,722,000.00
- FCF $448,664,000.00
- Revenue This Year
- SNDX $426.77
- FCF $14.21
- Revenue Next Year
- SNDX $98.31
- FCF $7.73
- P/E Ratio
- SNDX N/A
- FCF $12.88
- Revenue Growth
- SNDX N/A
- FCF N/A
- 52 Week Low
- SNDX $8.58
- FCF $13.54
- 52 Week High
- SNDX $25.07
- FCF $19.96
- Technical
- Relative Strength Index (RSI)
- SNDX 38.70
- FCF 72.33
- Support Level
- SNDX $8.77
- FCF $16.17
- Resistance Level
- SNDX $9.50
- FCF $16.22
- Average True Range (ATR)
- SNDX 0.53
- FCF 0.33
- MACD
- SNDX -0.04
- FCF 0.16
- Stochastic Oscillator
- SNDX 14.13
- FCF 97.65
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
About FCF First Commonwealth Financial Corporation
First Commonwealth Financial Corp functions in the financial services sector in the United States. Through its subsidiary, it offers a range of consumer and commercial banking services such as personal checking accounts, interest-earning checking accounts, savings accounts, insured money market accounts, investment certificates, fixed & variable rate certificates of deposit, and various kinds of loans. It also provides trust and wealth management services and offers insurance products. The company earns the majority of its revenue through net interest income.